Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
IDYA Quote, Financials, Valuation and Earnings
Last price:
$35.71
Seasonality move
:
-9.57%
Day range:
$35.19 - $35.92
52-week range:
$13.45 - $37.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.69x
P/B ratio:
2.86x
Volume:
355.1K
Avg. volume:
957.8K
1-year change:
41.03%
Market cap:
$3.1B
Revenue:
$7M
EPS (TTM):
-$1.86
Analysts' Opinion
-
Consensus RatingIDEAYA Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.65, IDEAYA Biosciences, Inc. has an estimated upside of 39.15% from its current price of $35.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.00 representing 100% downside risk from its current price of $35.68.
Fair Value
-
According to the consensus of 15 analysts, IDEAYA Biosciences, Inc. has 39.15% upside to fair value with a price target of $49.65 per share.
IDYA vs. S&P 500
-
Over the past 5 trading days, IDEAYA Biosciences, Inc. has overperformed the S&P 500 by 4.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
IDEAYA Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IDEAYA Biosciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter IDEAYA Biosciences, Inc. reported revenues of $207.8M.
Earnings Growth
-
IDEAYA Biosciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter IDEAYA Biosciences, Inc. reported earnings per share of $1.33.
Enterprise value:
2.4B
EV / Invested capital:
2.12x
Price / LTM sales:
14.69x
EV / EBIT:
--
EV / Revenue:
11.02x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
-22.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$210.8M
Return On Assets:
-14.12%
Net Income Margin (TTM):
-74.82%
Return On Equity:
-15.12%
Return On Invested Capital:
-14.79%
Operating Margin:
52.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $23.5M | $3.9M | $214.8M | -- | $207.8M | |
| Gross Profit | $20M | -$292K | $210.8M | -$1M | $206.8M | |
| Operating Income | -$119M | -$224.8M | -$208.9M | -$66.9M | $108.5M | |
| EBITDA | -$115.5M | -$220.5M | -$204.8M | -$65.9M | $109.5M | |
| Diluted EPS | -$1.95 | -$2.33 | -$1.86 | -$0.60 | $1.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $269M | $393.4M | $482.2M | $932.2M | $802.7M | |
| Total Assets | $399.4M | $410.9M | $532.9M | $1.2B | $1.2B | |
| Current Liabilities | $38.6M | $32.7M | $24.9M | $40.7M | $64.5M | |
| Total Liabilities | $81.8M | $42.1M | $24.9M | $59.5M | $93.1M | |
| Total Equity | $317.6M | $368.8M | $508M | $1.2B | $1.1B | |
| Total Debt | $3.9M | $2.1M | -- | $18.8M | $26.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$114.8M | -$149.7M | -$102.3M | -$49.2M | $142.2M | |
| Cash From Investing | -$56.8M | -$417.4M | -$29.6M | -$20M | $41.8M | |
| Cash From Financing | $222.1M | $815.7M | $30.4M | $286.5M | $301K | |
| Free Cash Flow | -$116.4M | -$153.3M | -$105.4M | -$49.7M | $142.2M | |
IDYA
Sector
Market Cap
$3.1B
$28.1M
Price % of 52-Week High
96.22%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-1.49%
-1.49%
1-Year Price Total Return
41.03%
-17.13%
Beta (5-Year)
0.040
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$34.29
200-day SMA
Buy
Level
$24.46
Bollinger Bands (100)
Buy
Level
24.89 - 33.07
Chaikin Money Flow
Buy
Level
4.2M
20-day SMA
Buy
Level
$34.53
Relative Strength Index (RSI14)
Buy
Level
61.99
ADX Line
Buy
Level
22.12
Williams %R
Neutral
Level
-35.1759
50-day SMA
Buy
Level
$32.62
MACD (12, 26)
Buy
Level
0.61
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
75.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.4967)
Buy
CA Score
(Annual)
Level (-0.0707)
Buy
Beneish M-Score
(Annual)
Level (-4.1321)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (5.1879)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, IDYA has received 13 Buy ratings 2 Hold ratings, and 0 Sell ratings. The IDYA average analyst price target in the past 3 months is $49.65.
-
Where Will IDEAYA Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that IDEAYA Biosciences, Inc. share price will rise to $49.65 per share over the next 12 months.
-
What Do Analysts Say About IDEAYA Biosciences, Inc.?
Analysts are divided on their view about IDEAYA Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IDEAYA Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $31.00.
-
What Is IDEAYA Biosciences, Inc.'s Price Target?
The price target for IDEAYA Biosciences, Inc. over the next 1-year time period is forecast to be $49.65 according to 15 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is IDYA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IDEAYA Biosciences, Inc. is a Buy. 13 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IDYA?
You can purchase shares of IDEAYA Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IDEAYA Biosciences, Inc. shares.
-
What Is The IDEAYA Biosciences, Inc. Share Price Today?
IDEAYA Biosciences, Inc. was last trading at $35.71 per share. This represents the most recent stock quote for IDEAYA Biosciences, Inc.. Yesterday, IDEAYA Biosciences, Inc. closed at $35.68 per share.
-
How To Buy IDEAYA Biosciences, Inc. Stock Online?
In order to purchase IDEAYA Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IDYA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IDYA
Sector
P/E ratio
--
23.89x
PEG ratio
-0.11x
-0.01x
P/B ratio
2.86x
1.81x
Price / LTM sales
14.69x
1.59x
Growth Metrics
IDYA
Sector
Revenue growth
78.48%
4.62%
Earnings growth
321.14%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.55
-$0.21
Profitability
IDYA
Sector
Profitability FY 2024
$3.2M
$3.6M
Return on invested capital
-14.79%
-31.84%
Return on assets
-14.12%
-27.96%
Return on equity
-15.12%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
10
Estimated Next Earnings Date
Feb
3
Balance Sheet
IDYA
Sector
Total cash
$786.9M
$26.4M
Short term investments
$591.9M
$25.7M
Total assets
$1.1B
$76.9M
Long term debt
$26.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
